Neuroglia in Tay-Sachs Disease: Neuronal Storage and Glial Response

Tay-Sachs disease primarily affects neurons, but neuroglia (astrocytes, microglia, oligodendrocytes) play critical roles in pathogenesis and response.

Primary Target: Neurons

• Neurons accumulate GM2 ganglioside in lysosomes → membranous cytoplasmic bodies (MCBs).
• Results in: synaptic loss, dendritic atrophy, axonal transport failure, metabolic stress, apoptosis.
• Most vulnerable: cerebral/cerebellar cortical neurons, brainstem nuclei, spinal motor neurons, retinal ganglion cells.

Glial Involvement

Microglia (Resident Immune Cells)

• Activated by neuronal damage signals (ATP, HMGB1, GM2 itself).
• Release pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), ROS, complement.
• Phagocytose debris; may exacerbate neuroinflammation.
• Dual role: clearance vs. bystander damage.

Astrocytes

• Reactive astrogliosis (GFAP↑, hypertrophy).
• Attempt homeostatic support: glutamate uptake, K⁺ buffering, antioxidant (GSH).
• But also contribute to glial scar, impede regeneration.
• May store GM2 secondarily (less than neurons).

Oligodendrocytes

• Myelin maintenance disrupted by neuronal loss & inflammation.
• Secondary demyelination contributes to conduction deficits.

Neuropathology Hallmarks

• Neuronal MCBs ("onion skin" inclusions) — EM diagnosis.
• Cortical atrophy, cerebellar atrophy, ventricular dilation.
• Reactive gliosis (microglia, astrocytes) in affected regions.
• Cherry-red spot: GM2 storage in retinal ganglion cells (except foveola).

Therapeutic Implications

• Neuron-targeted therapy essential (gene replacement, enzyme delivery).
• Anti-inflammatory modulation (microglial inhibitors) may slow progression.
• Substrate reduction therapy (miglustat) reduces GM2 synthesis in all cells.
• Biomarkers: neurofilament light (NfL), GFAP, inflammatory cytokines in CSF/blood.

While neurons are the primary victims, glial responses shape the neurodegenerative trajectory and offer adjunctive therapeutic targets.